IDNA
iShares Genomics Immnlgy & Hlthcr ETF
NAV as of
4 Week: 17.73 - 20.52
52 Week: 17.37 - 28.44
Latest Closing Price
20.18
Premium / Discount
-0.06
Expense Ratio
0.47%
Investment Objective
The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -19.83 | 1.67 | -11.88 |
| 1 Day | -0.93 | 0.00 | 0.00 |
| 1 Week | -1.66 | 4.62 | -0.36 |
| 1 Month | 16.18 | 11.37 | 1.42 |
| 3 Months | -7.94 | 15.32 | -0.52 |
| 6 Months | -16.02 | 18.81 | -0.85 |
| 1 Year | -25.87 | 27.09 | -0.95 |
| 2 Years | -57.45 | 47.26 | -1.22 |
| 3 Years | -53.85 | 55.62 | -0.97 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 54.4943 | -4.0033 | -42.1019 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 7.0000 | 82.0000 | 99.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| N.A | ||
Portfolio Data
Total Number of Holdings: 58
Number of Bond Holdings: 0
Number of Equity Holdings: 44
Total Market Value: 120,417,958
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Blueprint Medicines Corp | 5.5747 | 98,070 | 0 | 6,712,892 |
| 2 | Exelixis Inc | 5.3567 | 297,532 | 0 | 6,450,494 |
| 3 | Regeneron Pharmaceuticals Inc | 5.1166 | 7,718 | 0 | 6,161,279 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 16.41 |
| Large | 8.95 |
| Medium | 9.08 |
| Small | 25.29 |
| Micro | 35.62 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
18.5007
Price/Book*
1.7920
Price/Sales*
2.8789
Price/Cash Flow*
12.7844
Dividend Yield*
0.5762
Growth Measures
Long-Term Earnings
7.0689
Historical Earnings
76.0522
Sales Growth
30.7483
Cash-Flow Growth
39.6063
Book-Value Growth
4.1621
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
